Health Care Providers

The FAMILION tests open new options in the diagnosis of cardiac channelopathies and cardiomyopathies including LQTS, Brugada Syndrome, CPVT, HCM and ARVC.  The FAMILION family of tests can:

• Analyze specific genes to detect the mutations that cause cardiac channelopathies and cardiomyopathies
• Help diagnose LQTS, Brugada Syndrome, CPVT, HCM, ARVC and other associated disorders before patients exhibit symptoms
• Help determine the cause of the disorder
• Help determine whether a patient’s family members have the same mutation
• Guide treatment options and medication choices

It’s a simple test that’s leading to reduced uncertainty and more sophisticated diagnoses of cardiac channelopathies and cardiomyopathies.

Five archived teleconferences are available for specialists to increase awareness of LQTS, CPVT, Brugada Syndrome, and HCM genetic testing by providing current information to identify and manage LQTS, other channelopathies and HCM.

• Latest Treatment Strategies for the Long QT Syndromes
• Management of LQTS: From ECG to Genetics 
• Diagnostic, Prognostic, and Therapeutic Implications of Long QT Syndrome Genetic Testing
• Contemporary Strategies in the Evaluation and Management of Patients with Hypertrophic Cardiomyopathy
• Genetic Testing for HCM: Diagnostic, Prognostic, and Therapeutic Considerations

FAQs
Frequently asked questions about how FAMILION works and how it can be used to guide the course of treatment.

Technical Specifications
The science behind the FAMILION test

Resources
Study references and links to outside organizations that deal with LQTS, Brugada Syndrome, CPVT, HCM and associated disorders.

Test Instructions

1-877-2-PGXHEALTH (877-274-9432)